The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Data Analysis for Anti-Neoplastic Chemotherapy-Related Adverse Events Reported to the Korean Pharmacovigilance Regional Network

자발적 약물유해반응 데이터베이스를 이용한 항암제 유해사례 현황 분석

  • Lee, Ju-Yeun (College of Pharmacy and Institute of Pharmaceutical Science and Technology) ;
  • Jung, Jae-Woo (Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine) ;
  • Kang, Hye-Ryun (Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine) ;
  • Lee, Se-Hoon (Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine) ;
  • Kim, Hyang-Sook (Department of Pharmacy, Seoul National University Hospital, Seoul National University College of Medicine) ;
  • Cho, Sang-Heon (Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine)
  • Received : 2013.01.21
  • Accepted : 2013.03.27
  • Published : 2013.10.01
⟨ Previous Next ⟩

Abstract

Background/Aims: To describe the toxicity profile of anti-neoplastic agents from real clinical settings, we analyzed spontaneously reported adverse events (AEs) using data from the adverse drug reaction (ADR) reporting system of the Korean Food and Drug Administration (KFDA). Methods: Data were extracted from the nationwide spontaneous ADR reporting system of KFDA from July 2009 to December 2010. We extracted and analyzed data related to chemotherapy and identified unlabeled ADR that were not described in the package insert of the products. Results: In total, 5,867 cases of antineoplastic agent-related AE reports were identified after excluding cases for duplication and cases assessed as 'unlikely' and 'unclassifiable', based on expert opinion. Of the patients with AEs, 52.4% were males and the median age was 56 years. In total, 460 AEs (7.8%) from 267 patients were reported as 'serious' AEs. The most common causative anti-cancer drug class was pyrimidine analogs (31.5%), followed by platinum compounds (19.9%), protein kinase inhibitors (10.8%), and taxanes (8.8%). The most common clinical manifestation of AEs was gastrointestinal toxicities (25.5%), followed by skin disorders (25.3%), and generalized reactions (14.3%). In total, 168 cases (2.9%) of unlabeled AEs were identified. Among these, 10 were reported as serious AEs. Conclusions: The most common causative class of antineoplastic agents was that of pyrimidine analogs. Gastrointestinal and dermatological toxicities were the most common clinical chemotherapy-related adverse events. Further investigation and monitoring to evaluate causality associated with unlabeled AEs identified in this analysis are needed.

본 연구는 국내 자발적 보고된 항암제 유해사례에 대한 서술적 분석이었으며 가장 유해사례 보고가 많은 계열의 항암제는 pyrimidine 유사체였으며 항암제와 관련되어 가장 흔히 보고된 부작용 양상은 위장관계 부작용과 피부, 부속기계 부작용이었다. 또한 본 연구에서 확인된 미반영 유해사례에 대해서는 그 인과 관계를 평가하기 위해서 향후 지속적인 모니터링과 연구가 필요할 것으로 사료된다.

Keywords

References

  1. Medina PJ, Shord SS. Cancer treatment and chemotherapy. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: a Pathophysiologic Approach. 8th ed. New York: McGraw-Hill, 2011:2191-2228.
  2. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004;329:15-19. https://doi.org/10.1136/bmj.329.7456.15
  3. Gautier S, Bachelet H, Bordet R, Caron J. The cost of adverse drug reactions. Expert Opin Pharmacother 2003;4: 319-326. https://doi.org/10.1517/14656566.4.3.319
  4. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients: excess length of stay, extra costs, and attributable mortality. JAMA 1997;277:301-306. https://doi.org/10.1001/jama.1997.03540280039031
  5. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279:1200-1205. https://doi.org/10.1001/jama.279.15.1200
  6. Lundkvist J, Jönsson B. Pharmacoeconomics of adverse drug reactions. Fundam Clin Pharmacol 2004;18:275-280. https://doi.org/10.1111/j.1472-8206.2004.00239.x
  7. Lapeyre-Mestre M, Gary J, Machelard-Roumagnac M, Bonhomme C, Bugat R, Montastruc JL. Incidence and cost of adverse drug reactions in a French cancer institute. Eur J Clin Pharmacol 1997;53:19-22. https://doi.org/10.1007/s002280050331
  8. Hassett MJ, O'Malley AJ, Pakes JR, Newhouse JP, Earle CC. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst 2006;98:1108-1117. https://doi.org/10.1093/jnci/djj305
  9. Ladewski LA, Belknap SM, Nebeker JR, et al. Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports project. J Clin Oncol 2003;21:3859-3866. https://doi.org/10.1200/JCO.2003.04.537
  10. Lim KH, Shin HT, Sohn HS, et al. Comparison of WHO-ART versus MedDRA, internationally standardized terminology of adverse drug reaction classification. Korean J Clin Pharm 2007;17:46-51.
  11. World Health Organization Uppsala Monitoring Center. The WHO adverse reaction terminology [Internet]. Uppsala: World Health Organization Uppsala Monitoring Center, c2012 [cited 2012 Jan 16]. Available from: http://www.umcproducts. com/graphics/3149.pdf.
  12. World Health Organization. Collaborating Centre for Drug Statistics Methodology, ATC index with DDDs [Internet]. Oslo: WHO, c2008 [cited 2008 Dec 16]. Available from: http://www.whocc.no/atc_ddd_index.
  13. National Cancer Institute. Common terminology criteria for adverse events (CTCAE) version 4.03 [Internet]. Maryland (MD): National Cancer Institute, c2010 [cited 2010 June 20]. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/ CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf.
  14. Rawlins M, Thompson W. Mechanisms of adverse drug reactions. In: Davies D, ed. Textbook of Adverse Drug Reactions. New York: Oxford University Press, 1991:18-45.
  15. Puche Canas E, Luna Del Castillo JD. Adverse drug reactions in patients visiting a general hospital: a meta-analysis of results. An Med Interna 2007;24:574-578.
  16. Tran C, Knowles SR, Liu BA, Shear NH. Gender differences in adverse drug reactions. J Clin Pharmacol 1998;38:1003-1009. https://doi.org/10.1177/009127009803801103
  17. Ciorciaro C, Hartmann K, Kuhn M. Differences in the relative incidence of adverse drug reactions in relation to age? an evaluation of the spontaneous reporting system of SANZ (Swiss Drug Monitoring Center). Schweiz Med Wochenschr 1998;128:254-258.
  18. Kubota T. The role of S-1 in the treatment of gastric cancer. Br J Cancer 2008;98:1301-1304. https://doi.org/10.1038/sj.bjc.6604332
  19. Ha T, Kwon SJ. Efficacy and safety profile of TS-1 or TS-1/CDDP in patients with advanced gastric cancer. J Korean Gastric Cancer Assoc 2006;6:139-145. https://doi.org/10.5230/jkgca.2006.6.3.139
  20. Malet-Martino M, Martino R. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. Oncologist 2002;7:288-323. https://doi.org/10.1634/theoncologist.7-4-288
  21. Gähler A, Hitz F, Hess U, Cerny T. Acute pericarditis and pleural effusion complicating cytarabine chemotherapy. Onkologie 2003;26:348-350. https://doi.org/10.1159/000072094
  22. Hermans C, Straetmans N, Michaux JL, Ferrant A. Pericarditis induced by high-dose cytosine arabinoside chemotherapy. Ann Hematol 1997;75:55-57. https://doi.org/10.1007/s002770050312
  23. Morisaki T, Ohnita K, Takeshima F, et al. A case of sclerosing cholangitis caused by oral chemotherapy with S-1. Nihon Shokakibyo Gakkai Zasshi 2011;108:245-252.
  24. Van Dam FS, Schagen SB, Muller MJ, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 1998;90:210-218. https://doi.org/10.1093/jnci/90.3.210
  25. Hospira. Methotrexate prescribing information [Internet]. Illinois (IL): Hospira, c2012 [cited 2012 Jun 5]. Available from: http://www.hospira.com/Images/432925_32-91319_1.pdf
  26. U.S. National Library of Medicine. Nolvadex prescribing information [Internet]. Maryland (MD): U.S. National Library of Medicine, c2012 [cited 2012 Jun 5]. Available from: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id= 3420.
  27. Amptoulach S, Tsavaris N. Neurotoxicity caused by the treatment with platinum analogues. Chemother Res Pract 2011;2011:843019.
  28. New Zealand Medicines and Medical Devices Safety Authority. $DBL^{TM}$ Cisplatin injection, prescribing information [Internet]. New Zealand Medicines and Medical Devices Safety Authority, c2012 [cited 2012 Jun 5]. Available from: http://www.medsafe.govt.nz/profs/datasheet/c/ Cisplatinmaynepharmainj.pdf.
  29. O'Dwyer JP, Clabby C, Crown J, Barton DE, Hutchinson M. Fragile X-associated tremor/ataxia syndrome presenting in a woman after chemotherapy. Neurology 2005;65:331-332. https://doi.org/10.1212/01.wnl.0000168865.36352.53

Cited by

  1. Analysis of data on capecitabine-related adverse drug reactions from the Korean adverse event reporting system database vol.34, pp.None, 2013, https://doi.org/10.1016/j.ejon.2018.03.004
  2. 교모세포종으로 항암화학치료 이후 설사를 호소하는 소음인 치험 1례 vol.31, pp.4, 2019, https://doi.org/10.7730/jscm.2019.31.4.65
  3. The Characteristics of Adverse Drug Reactions in Cancer Patients: An Analysis of Spontaneously Reported Cases vol.95, pp.2, 2013, https://doi.org/10.3904/kjm.2020.95.2.104
  4. 폐 전이된 진행성 직장암의 항암화학치료 후 부종에 대한 태음인 치험 1례 vol.33, pp.4, 2013, https://doi.org/10.7730/jscm.2021.33.4.10